Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.45 -1.67 (-2.35%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
3 Promising Growth Stocks You Can Buy for Less Than $100
Via The Motley Fool
How Does D-Wave Stack Up Against Quantum Competitors?
D-Wave, IonQ, and Rigetti are three of the most talked-about quantum computing firms; how do these three companies stack up against one another? 
Via MarketBeat
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
From AstraZeneca
Via Business Wire
What Does the Market Think About AstraZeneca?
Via Benzinga
Earnings Scheduled For April 29, 2025
Via Benzinga
George Soros Loads Up On First Solar Calls: What Does He Know That Wall Street Doesn't?
Soros Fund Management, in a surprise move, revealed a bold new bet on First Solar Inc., scooping up 1.6 million call options. 
Via Benzinga
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
P/E Ratio Insights for AstraZeneca
Via Benzinga
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
From AstraZeneca
Via Business Wire
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens
The company noted that no new safety concerns were identified with the combination of Imfinzi and BCG induction and maintenance therapy in the trial. 
Via Stocktwits
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
Via Benzinga
Topics ETFs Government
Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential. 
Via MarketBeat
Topics Artificial Intelligence
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
From AstraZeneca
Via Business Wire
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." 
Via Benzinga
Topics Artificial Intelligence
AstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment Dips
The approval is based on positive results from a phase 3 trial, which demonstrated that Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to... 
Via Stocktwits
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients. 
Via Benzinga
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Topics Artificial Intelligence
AstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s Positive
AstraZeneca said on Friday that the full results from the two trials will be shared with regulatory authorities and presented at an upcoming medical meeting. 
Via Stocktwits
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
From AstraZeneca
Via Business Wire
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty
AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer. 
Via Benzinga
AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops
Shares were little moved despite a strong earnings beat. 
Via Investor's Business Daily
Topics Earnings Government
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this... 
Via Benzinga
AstraZeneca's Q1 2025 Financial Results
From AstraZeneca
Via Business Wire
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
Via Benzinga
Topics Artificial Intelligence
Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?
Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.